This article is more than 5 years old. Information may no longer be current.

Triamcinolone may lower risk of macular edema in uveal melanoma patients, study suggests

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Among patients with uveal melanoma, treatment with periocular triamcinolone after plaque radiotherapy may significantly lower the risk of macular edema, a comparative study found. However, at 24 months of follow-up, the rate of vision loss is not significantly changed.

Noel Horgan, MD, and colleagues evaluated the potential benefit of periocular depot triamcinolone for preventing macular edema after performing iodine-125 plaque radiotherapy on 87 patients with uveal melanoma. Specifically, 55 patients received 40 mg of periocular triamcinolone at the time of plaque application and 4 and 8 months later; 32 controls were treated without triamcinolone.

Patients were evaluated at 4, 8, 12, 18 and 24 postoperative months.

According to multivariate analysis, eyes treated with periocular triamcinolone had a significant reduction in the risk of radiation-induced macular edema (P = .002; hazard estimate = 0.49), the authors reported.

Triamcinolone-related adverse effects included IOP elevation in 7% of cases and blepharoptosis in 5% of cases, according to the study, published in the July issue of Retina.